Klotho Neurosciences enters exclusive global gene therapy license with AAVnerGene

Greenland Mines Ltd

Exclusive global rights to AAVnerGene's AAVone platform for three gene therapy programs: KLTO-101, KLTO-202, KLTO-303.
Initial license fees: $250,000 (first product) to $500,000 (third product); plus 2% royalty on revenue.
Targets Alzheimer's, Parkinson's, ALS, motor neuron diseases, and aging-related pathologies.
CEO cites faster, cheaper manufacturing with higher purity and lower toxicity via AAVone and ATHENA platforms.
Partnership aims to accelerate clinical development and reduce high drug price/dose-related toxicity.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.